ARTICLE | Company News
Applied Molecular other research news
September 10, 2001 7:00 AM UTC
AMEV received a $1.03 million Phase II SBIR grant from the National Institute of General Medical Sciences to use its AMEsystem to optimize butyrylcholinesterase, a serum protein that hydrolyzes cocai...